Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more
KROS moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 54 cases where KROS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on KROS as a result. In 70 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on September 21, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for KROS crossed bullishly above the 50-day moving average on August 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +4.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 230 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 190 of 237 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
KROS broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.887) is normal, around the industry mean (25.951). P/E Ratio (4.778) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (436.793).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology